Combining oncology drug development and biomarker technology experience to improve cancer care
Executive Vice President and Chief Operating Officer
Vicki Kelemen has served as Executive Vice President and Chief Operating Officer since 2020, and previously as Vice President of Clinical Development and Investor Relations since 2018, and Vice President of Corporate Communications from 2017 to 2018 and Senior Director of Marketing Communications from 2015 to 2017.
Prior to joining Trovagene, Ms. Kelemen was Sr. Vice President at a global healthcare communications agency, where she specialized in the market development and commercialization of therapeutics for serious and rare diseases, as well as the development of patient advocacy programs. Previously, Ms. Kelemen held progressive operations, marketing and communications management and executive positions and lead the development and launch of several novel products with pharmabiotech companies focused in therapeutics, including Amylin, Maxim, Agouron (Pfizer), Valeant, Ardea Biosciences and Dura Pharmaceuticals. Ms. Kelemen began her career in healthcare with Bayer Pharmaceuticals, where she held positions is sales, sales training, and marketing.
Ms. Kelemen has a BS degree from the University of California at Davis.